Orchestra BioMed Price To Book vs. Book Value Per Share
| OBIO Stock | 5.77 0.33 6.07% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.12 | 0.9326 |
|
|
For Orchestra BioMed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Orchestra BioMed to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Orchestra BioMed Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Orchestra BioMed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Orchestra BioMed Holdings over time as well as its relative position and ranking within its peers.
Orchestra |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Orchestra BioMed Holdings Book Value Per Share vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Orchestra BioMed's current stock value. Our valuation model uses many indicators to compare Orchestra BioMed value to that of its competitors to determine the firm's financial worth. Orchestra BioMed Holdings is considered to be number one stock in price to book category among its peers. It also is considered to be number one stock in book value per share category among its peers creating about 0.26 of Book Value Per Share per Price To Book. The ratio of Price To Book to Book Value Per Share for Orchestra BioMed Holdings is roughly 3.88 . At this time, Orchestra BioMed's Book Value Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orchestra BioMed's earnings, one of the primary drivers of an investment's value.Orchestra Book Value Per Share vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Orchestra BioMed |
| = | 4.72 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Orchestra BioMed |
| = | 1.22 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Orchestra Book Value Per Share Comparison
Orchestra BioMed is currently under evaluation in book value per share category among its peers.
Orchestra BioMed Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Orchestra BioMed, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Orchestra BioMed will eventually generate negative long term returns. The profitability progress is the general direction of Orchestra BioMed's change in net profit over the period of time. It can combine multiple indicators of Orchestra BioMed, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -10 K | -10.5 K | |
| Net Interest Income | 3.8 M | 4 M | |
| Interest Income | 3.8 M | 4 M | |
| Operating Income | -51.5 M | -48.9 M | |
| Net Loss | -49.1 M | -51.6 M | |
| Income Before Tax | -49.1 M | -51.6 M | |
| Total Other Income Expense Net | 2.4 M | 2.5 M | |
| Net Loss | -20.7 M | -21.7 M | |
| Net Loss | -49.1 M | -51.6 M | |
| Income Tax Expense | 119.1 K | 113.2 K | |
| Change To Netincome | 501.3 K | 476.2 K | |
| Net Loss | (1.48) | (1.55) | |
| Income Quality | 0.94 | 1.07 |
Orchestra Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Orchestra BioMed. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Orchestra BioMed position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Orchestra BioMed's important profitability drivers and their relationship over time.
Use Orchestra BioMed in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.Orchestra BioMed Pair Trading
Orchestra BioMed Holdings Pair Trading Analysis
The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.
The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Orchestra BioMed position
In addition to having Orchestra BioMed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Education Thematic Idea Now
Education
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
To fully project Orchestra BioMed's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Orchestra BioMed Holdings at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Orchestra BioMed's income statement, its balance sheet, and the statement of cash flows.